Index

Note:
Abbreviations used in the index are listed on pages xiv–xviii
Drug and product names are in bold
Page numbers in italics refer to figures and boxes; those in bold refer to tables.

A
abacavir 249
abbreviated New Drug Application (ANDA) (US) 478, 487, 502–503
criteria for approval 487
generic drug competition, impact of 519
abiraterone 274
ABPI Code of Practice see Association of British Pharmaceutical Industry (ABPI), Code of Practice
absolute rate reduction (ARR) 204, 205
absorption (of drugs) 114, 114
bioavailability definition 120
children/adolescents, developmental pharmacokinetics 297
enhancement 33
see also plasma concentrations
absorption, distribution, metabolism, excretion and toxicological (ADMET) properties 3
abuse potential
preclinical safety pharmacology studies 52
reporting 242
academia, collaboration strategies with companies 5, 9, 23–24, 219, 220
academic drug discovery sector 23
accelerated approval see under registration
accelerometer mass spectrometry 126
access, of patient (to drugs) 504–505, 577–582
accessory, as medical device 422
accountability
investigational medicinal products 165, 166
records 165
accreditation, online medicines 605
ACE inhibitors 16
acacetaminophen, metabolite 69–70
acetylcholine, reduced activity in Alzheimer’s disease 14
acetylcholinesterase (AChE) inhibitors 14–15
acid-labile drugs 33
acquired immunodeficiency syndrome (AIDS) see AIDS
active comparator see under controlled clinical trials
active implantable medical devices (AIMDs) 419
active medical devices 423
active substances, and similar active substances 372
acute coronary syndrome 16
acute toxicity 87–88
adalimumab (Humira) 20
adaptive licensing 531
adjuvant(s), for vaccines 266–267
novel 267
adjuvant therapy, cancer 271
ADME characteristics 114
drug interaction studies 122
information, preclinical safety testing 43, 87
radiolabelled drug study, metabolite toxicology 70
ADMET properties 3
Administration of Radioactive Substances Advisory Committee (ARSAC) 126
approval for trial 171
administration routes first-in-human trials 97, 106
preclinical safety pharmacology studies 50
preclinical safety testing 68, 68–69
biologics 74
carcinogenicity studies 56–57
risk minimisation in volunteer studies 106
see also drug delivery (administration); oral administration route; other specific routes
adolescents
paediatric clinical trials 301
vaccines 255
see also children; minors; paediatric drug development
β-adrenoceptor agonists 17
ADROIT 334
Advanced Therapy Medicinal Products (ATMPs)
EC Regulation 374, 641
Medicines for Human Use Regulations 2012 614
tissue engineered products 431–432
adverse drug reaction (ADR) 721
augmented (type A) 174, 175, 246
Australia, regulation of therapeutic products 569, 579–580, 581
black triangle scheme 330, 332
collection and collation 241
common reactions 246
CSM Subcommittee 327, 331
definition 173–174, 235, 240
demography, UK Register 331
EudraVigilance database 413
fatal or life-threatening 579
see also life-threatening adverse events
frequency 43, 249
history of monitoring 322–323
ICH GCP 173–174, 235
see also International Conference on Harmonisation (ICH)
interim reviews, first-in-human trials 106–107
Japan 546
major drugs withdrawn 333
see also drug withdrawal
non-prescription drugs 396
number of monitored patients 333
number of patients needed to detect 174
number of reports 330, 331, 333, 344
paediatric 437
prediction by preclinical safety pharmacology studies 50
prescription drugs 479, 485
rechallenge after 175
regulations 330–335

© 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd.
reporting 241–242
clinical trials 243, 350–351
doctor (by) 331, 331–332, 332
EU Clinical Trial Directive 350–351
health care practitioners (by) 333
national legal requirements 241–242
patients (by) 333
protocol instructions 158
rates of 330
spontaneous 330
see also Yellow Card scheme
SAMM guidelines 767–770
serious 359
in clinical trials 781
doctor reports 331
incidence 235
percentage of reports 332
see also serious adverse events (SAEs)
severe 351
therapeutic dose relationship 96
types (A-F) 174, 175, 246
unexpected 175, 579
volunteer studies 95–96
see also TGN1412 (CD28 antibody)
yellow card scheme see Yellow Card scheme
adverse effects, biologicals 134
adverse events 505, 528
Australia, regulation of therapeutic products 579–580, 581
causality establishment 174–175, 246–247
degrees of certainty 175
see also causality (adverse events)
coding 242
collection and collation 241
definition 174, 240
determining clinical significance 175–176
Eudamed 432
global introspection 175
influencing later development study design 221
life-threatening 174, 175, 241, 243
medical devices 432
NDA, power to order new safety legislation 437
over-reporting, detecting 247
paediatric regulation 437
product quality complaints and 242
reporting 174–175
to ethics committees 176
EU Clinical Trial Directive 350–351
on medical devices 432
protocol instructions 158
serious see serious adverse events
(SAEs)
unexpected 175, 511
adverse experience see adverse events
Adverse Reaction Leaflet 332, 333
advertising
ABPI Code see Association of British Pharmaceutical Industry (ABPI), Code of Practice
Australian regulations 583–584
methods 583
prescription medicines 583
authorised medicinal products 642–643
to health professionals 643
campaign, for clinical trials 172
clinical trial subjects, ABPI guideline 766
complaints 673, 675, 676–677
definition 412
EU, human medicinal products 410–413
see also EU Procedures
FDA regulation 488–489
non-prescription drugs 476–477
prescription drugs 488–489
to health professionals 412
herbal medicines 672
internet, prescription drugs 681
Japan 546
legislation 671–672, 677–678
enforcement 673–678
MHRA role 673
see also Association of British Pharmaceutical Industry (ABPI), Code of Practice
legislation, controls/codes 672, 673–678
methods 488
monitoring 412, 672–673
of published material 672–673
off-label 527
over-the-counter (OTC) drugs 395
prescription drugs 643, 670, 681
USA 488, 490, 527
regulations 412–413
UK prosecution over 336
UK regulations 336
unauthorised medicinal products
unlicensed medicines 672
for individual patient use 615, 618–619
vetting of material 672
voluntary control 412–413
Code of Practice (ABPI) 413
see also information; promotion
Advertising Standards Authority (ASA) 677
advisors, professional, information and promotion 678
Advisory Board on the Registration of Homeopathic Products (ABRH) 338
Advisory Committee on Prescription Medicines (ACPM) 566–567
activities, and members 567
Advisory Committees 235
aerosols, preclinical safety testing 69
aliberecept 274
age limits for elderly in controlled trials 151
for healthy volunteers 92
age of majority/minority 352
age-related changes
pharmacokinetics 124–125
see also elderly
agreement, contractual 96
AIDS 13
investigational new drug (IND) 481
patient freedom of choice 492
see also HIV infection
albumin, binding of drugs 297
alcohol, pharmacokinetics in liver disease 125
alert card 163
algorithms, causality (product and adverse event) 247
aliskiren 16
All Wales Medicines Strategy Group (AWMSG), economic evaluation 704
allergic contact dermatitis 66
alum (adjuvant) 267
Alzheimer’s disease, drug discovery 14–16
amendments to trials 178, 178, 178
urgent 178
see also protocol of studies
Ames test 88
aminoglycoside antibiotics 119–120
amiodarone 45
atrial fibrillation 16
side effects 16
amyloid plaques 14, 15
analysis of controlled clinical trials see controlled clinical trials; data analysis
analysis of covariance (ANCOVA) 212, 212–213, 213
analytical method development 32
impurity detection 71
anastrozole 274
ANCOVA 212, 212–213, 213
androges, prostate cancer, as target for therapy 274
aneugens 61
aneuploidy 61
angioedema, hereditary 16
angiotensin-converting enzyme (ACE) inhibitors 16
angiotensin II receptor blockers (ARBs) 16
animal(s), use in research, three R’s 44
Animal and Scientific Procedures Act (1986 UK) 633
animal drugs, regulation 474
animal rights 44
animal species
preclinical safety testing 43, 49, 52
carcinogenicity studies 56
reproductive toxicology studies 60
species-specific products and effects 67–68
biotechnology-derived products 73, 74
pharmacokinetics 87
animal testing 42, 43, 480
Animal and Scientific Procedures Act (1986 UK) 633
breeding and supply of experimental animals 632–633
Committee on Safety of Drugs (CSD) requirement 325
cosmetic sector 633
costs 76–78, 77
ethical issues 44, 76–78, 77, 632–633
European Law 633
harmonisation 633
IND not required 480
legal control objectives 632
legal issues relating to medicinal products 632–633
Marketing Authorisation Application (MAA) 633
media coverage 633
minimisation 66, 78
non-human primates see non-human primates
numbers of animals 76–78, 77
pharmaceutical sector, ban status 633
premises 632
rationale for 43
reliance, phases of clinical development 48
research staff 632
rodents and non-rodents 43, 49, 52
see also rodents, preclinical safety testing
teratogenicity 325
see also preclinical safety testing
annual financial returns (AFR), Pharmaceutical Price Regulation Scheme 711
anti-arrrhythmic drugs 16 anti-inflammatory drugs 17 inflammatory bowel disease 19 metabolism 125
antibiotics 486 amendments to FD&C Act 464 IND and NDA requirements (US) 486 antibodies antidrug see antidrug antibodies (ADAs)
as cancer drugs 275, 283 chimeric 133, 134 human 133, 134 humanised 133, 134 isotypes, novel adjuvants affecting 267 mouse 133 neutralising 75 structure 132–134, 133 transfer across placenta 76 vaccine immunogenicity measurement 259 antibody response 132, 259, 260 anticancer drugs 13 see also cancer drugs/therapy anticounterfeiting strategy legislative framework 605–606 Prescription Drug Marketing Act 607 public awareness 605 technology 606–607 see also counterfeit medicines antidepressants, full development, study number 228 antidote, first-in-human study 106 antidrug antibodies (ADAs) 74–75 cross-reactivity 138 formation 74–75 sustaining 139 three-tiered approach to detection 138–139 antifungal drugs, development 22 antihypertensive drugs, development 9 antimalarial drugs artesunate 602–603 counterfeited 602–603 development 21 antineoplastic drugs 13 see also cancer drugs/therapy antioxidants 41, 69 antiretroviral drugs counterfeit 603 see also HIV infection antisense oligonucleotides 20 antiviral drugs, counterfeit 603 apothecaries 320 applications integrity (fraud) policy’ 487–488 apameters 20 archiving of documents 181–182 area under plasma concentration–time curve see AUC (time–concentration curve) arithmetic mean see mean (arithmetic) aromatase inhibitors 273–274, 274 ArrayTrack software 46 arrhythmias, preclinical safety pharmacology 51 ascaridole 322 arsphenamine, counterfeited 602–603 AS01 adjuvant 267 aseptic manufacture 38, 39–41 criteria controlled during 39–40 assay sensitivity 212
failure in phase III trials 282
future perspectives 283
history 270
ligands as target 273, 273–274
likelihood of efficacy 280
maximum tolerated dose (MTD) 271, 279
NME approved 6, 7, 8
number of drugs under development 220
pharmacogenetics/pharmacogenomics 276–277
preclinical testing 271–272, 273, 274–275
EGF 274–275
VEGFR 274
regulation of development 282–283
resistance to, mechanisms 277–279, 282–283
pharmacokinetics in FIH studies 99
maximum tolerated dose (MTD) 271, 273
likelihood of efficacy 280
history 270
future perspectives 283
failure in phase III trials 282
Best Pharmaceuticals for Children Act (2002 US) 228, 437, 469–470
BNF for 622
body composition and drug distribution 297
clinical trial subjects 351–352, 353
consent 289, 291
see also assent
demography and 435
developmental pharmacokinetics 297
dosages 297, 435
evaluation 297–298
ethics of research in 289, 291, 298
EU Clinical Trials Directive 352
see also EU Clinical Trials Directive
healthy, as volunteers in trials 301
exclusion 352
indication expansion 594
legal representation 352
metabolism of drugs 297
off label drugs see off label drugs
phase I studies of vaccines 260
phase III studies 228
physiology, special paediatric 435, 437
regulation of drugs (EU) see paediatric Regulation (EU)
unlicensed medicines, use of 622–623
vaccines 255
see also minors; paediatric drug development; paediatric Regulation (EU)
chimeric antibodies 133, 134
China, emerging markets 732
chymotrypsinogen 925, 297
chloramphenicol 331
chloroform 322, 327
CHMP guidelines see Committee for Medicinal Products for Human Use (CHMP)
choice, patient freedom of 492
cholesterol 125–126
cholesteryl-lowering drugs see statins
choline fenofibrate 16
cholinergic neurones, loss, in Alzheimer’s disease 14
chromosomal aberrations, loss, in Alzheimer’s disease 14
assays for 63
cytogenetic test 62
numerical 61
structural 61
chromosomal mutations 61
chronic disease, phase III studies 229
chronic myeloid leukaemia (CML) 278
chronic obstructive pulmonary disease (COPD) 278
drug discovery 62
chiral ‘tags,’ inert 10
chief investigator, ethics committee 170
child resistant packaging 582–583
Child–Pugh classification 125, 152
children
absorption of drugs 297
Best Pharmaceuticals for Children Act (2002 US) 228, 437, 469–470
BNF for 622
body composition and drug distribution 297
clinical trial subjects 351–352, 353
consent 289, 291
see also assent
demography and 435
developmental pharmacokinetics 297
dosages 297, 435
evaluation 297–298
ethics of research in 289, 291, 298
EU Clinical Trials Directive 352
see also EU Clinical Trials Directive
healthy, as volunteers in trials 301
exclusion 352
indication expansion 594
legal representation 352
metabolism of drugs 297
off label drugs see off label drugs
phase I studies of vaccines 260
phase III studies 228
physiology, special paediatric 435, 437
regulation of drugs (EU) see paediatric Regulation (EU)
unlicensed medicines, use of 622–623
vaccines 255
see also minors; paediatric drug development; paediatric Regulation (EU)
chimeric antibodies 133, 134
China, emerging markets 732
chymotrypsinogen 925, 297
chloramphenicol 331
chloroform 322, 327
CHMP guidelines see Committee for Medicinal Products for Human Use (CHMP)
choice, patient freedom of 492
cholesterol 125–126
cholesteryl-lowering drugs see statins
choline fenofibrate 16
cholinergic neurones, loss, in Alzheimer’s disease 14
chromosomal aberrations, loss, in Alzheimer’s disease 14
assays for 63
cytogenetic test 62
numerical 61
structural 61
chromosomal mutations 61
chronic disease, phase III studies 229
chronic myeloid leukaemia (CML) 278
chronic obstructive pulmonary disease (COPD) 278
drug discovery 62
chronic toxicity 88
Cimetidine 122
Cirrhosis, advanced decompenated 125
Cisplatin 270
term and early termination 641, 761–762
third parties’ rights 762
publicity 760
waiver 762
see also contractual arrangements (in clinical research)
clinical trial authorisation (CTA) 349
amendments 178
application and time frame 171, 403–404
non-interventional studies 403
EU requirement for, under Directive 329
request for 90–91
Clinical Trial Certificate (CTC) 327, 328–329
exemption 329
clinical trial coordinator, role 184
clinical trial notification (CTN) 578
application 578
Australian regulation 558
Japan, rates in 548
notification fee 578
record 578
Clinical Trials Directive see EU Clinical Trials Directive (2001/20/EC)
Clincial Trials Coordinator, role 184
clinical trial notification (CTN) 578
post-authorisation 226, 404
premature termination 171–172
see also stopping
prioritisation 233
quality control/assurance see quality assurance (QA); quality control (QC)
quality management 183–186
see also quality assurance (QA); quality control (QC)
randomised controlled see randomised clinical trials (RCTs)
recruitment see recruitment (for trials)
regulatory inspections and QA audits 232
reliance on animal toxicity data 48
special populations 151–152, 226
sponsor see sponsor(s)
supplies for, full development plan 229–230
SUSARs see suspected unexpected serious adverse reactions (SUSARs)
suspension 350, 779
therapeutic vaccines 268
transparency 445
uncontrolled 145
vaccines see vaccine(s)
Voluntary Harmonised Procedure 357
vulnerable subjects see vulnerable subjects
clinical trial agreement
breaches of 641
clinical trial governance 640
confidence 641, 759
dispute resolution 762
financial arrangements 761
force majeure 762
freedom of information 641
indemnity provision 641, 758
intellectual property 642, 760
investigational medicinal product (IMP) supply/disposal 640
limitations of liability 640
model (mCTA) 640, 641
modification 762
parties to CTA 640, 762
obligations 640, 757
party negotiation 640–641
fixed-dose 593
for HIV infection treatment 13
combinatorial chemistry 24
computational method advances 10, 24
impact on drug discovery 9–10
library synthesis 9, 10
natural products 22
shortcomings 10
solid-phase technologies 9
’split-and-mix’ technology 9–10
combinatorial libraries 9, 10
 Comet assay for DNA damage 64
commercial review, due diligence report 321
commercialisation of medicines 740–741
Commission on Human Medicines (CHM) 338, 339–340
chairman 339
expert advisory groups (EAGs) 340
functions 339–340
operation, arrangements 340
subcommittees 340
Commission Regulations see EU Regulations
Committee for Advanced Therapies (CAT) 374
functions, and members 374
Committee on Dental and Surgical Materials (CDSM) 328
Committee for Herbal Medicinal Products (HMP) 341, 365, 372–373
activities, and structure 372
Committee for Medicinal Products for Human Use (CHMP) 343, 370–371, 612, 613
centralised procedure 384
chairmen 371
function 371
guidelines 371
dependent potential of drugs 72
dose selection for biologicals 140
first-in-human trials 67, 140
genotoxic impurities 71, 72
sensitisation assays 66
Marketing Authorisation Application (MAA) Opinion 385
Paediatric Committee members 373
pharmacovigilance role 371
safety-related referral to CHMP 415
preclinical safety pharmacology core
battery 51
preclinical safety testing guidelines 44
rapporteur 371
referrals (EU) 371, 408–410
EU Procedures 408–410
fees 409
Opinion of CHMP 409
safety-related 415
time-frame 409
responsibilities 371
scientific advice and protocol
assistance from 400–402
scientific advisory groups (SAGs) 375, 376–377
answers and comments 377
members 377
structure/membership 370–371, 375
Committee for Orphan Medicinal Products (COMP) 371–372
application to 398
incentives for orphan medicines 372
market exclusivity 372
Opinion of, in response to application 398
Index

Committee for Proprietary Medicinal Products (CPMP) 51, 558, 562, 580
Australia and 562, 569
centralised procedure 384
chairmen 341
establishment 341
role/responsibilities 365
'old' 363
Safety Working Party 325
Working Party 372, 376
Committee on the Review of Medicines (CRM) 328
subcommittees, and functions 328
Committee on Safety of Drugs (CSD) 324–325
adverse drug reaction studies 330
on clinical trials 324–325
drugs withdrawn 330–331
subcommittees, and roles 324
teratogenicity testing 325
teratogenicity testing 325
term of reference 324
see also Committee on Safety of Medicines (CSM)
Committee on Safety of Medicines (CSM) 325, 327–328, 329
functions 327, 338
general safety recommendations 335–336
Subcommittee on Adverse Reactions 327, 331
transition from CSD 327
Yellow Card scheme and 331
Common Drug Review (CDR), Canada, economic evaluation 702–703
Common Technical Document (CTD) 222, 344, 365, 382, 450, 512–513
administrative and prescribing information 449
agreement on (ICH) 365, 449, 512–513
benefits for authorities and applicants 451
clinical study reports 450
contents 449–450
data requirements 542
developments (2002) 453–454
Directive requirements for 365
e-CTD, TGA registration 562
efficacy 452
feasibility study 449
format 365, 543
formatted dossiers 453
generic and OTC drugs 449
harmonisation and 344, 450
hurdles for 451–452
ICH 5 meeting report 449–450, 451
ICH 6 454
ICH-CTD, organisation 543
impact on non-ICH countries 453
implementation 450–451
Japan and 541–542
Marketing Authorisation Application (MAA) 381
non-clinical study reports 450
organisation (modules) 449–450, 450, 451, 543
pharmacopoeias 451, 452
post-ICH 5 451–454
preparation 344
problems for regulatory agencies/industry 452–453
quality 449–450, 451
regional differences 451
safety 452
summaries 449
see also International Conference on Harmonisation (ICH)
common technical specifications (CTS), in vitro diagnostics (IVDs) 431
Commonwealth Department of Health 554, 556
Commonwealth Therapeutic Goods Act (1989) 554, 557, 558
communication 449
enhanced, risk minimisation 251
in full development plan 233
late clinical development in emerging markets 738
see also information; promotion
Community Care Act (1990 UK), National Health Service and 709
Community Trade Mark (CTM) 647–648
Office of Harmonisation 647
Company Core Data Sheet (CCDS) 245, 250
information included 249–250
as platform for risk management 250
comparative toxicogenomics database 46
comparators see active comparator
compassionate use 387, 687
centralised EU application 387–388
investigational new drug (IND) 481
Japan 546
open trials 147
supply of unlicensed medicines for individual patient use 612–613, 623
see also unlicensed medicine supply, individual patient use
compensation (for clinical trials) guidelines and indemnity (Australia) 581
paediatric clinical trials 300
trial subjects 291
ABPI guidelines 160
for volunteers 96, 291
competence (capability)
for informed consent 288
mentally/physically incapable
informed consent 161, 290, 291
see also consent
competent authority, medical devices 421
competitive advantage, studies to demonstrate 225, 228
competitor intelligence 661
complaints
advertising see advertising
product quality 242
Safety Assessment of Marketed Medicines studies 769
complementarity determining regions (CDR) 132, 133
complementary medicines, Australia, regulations 555, 584, 585
Complera 13
complex polypeptides, assembly 9
compliance
late clinical development in emerging markets 738
legislation/legal requirements 236
pharmacovigilance, EU Procedures 415–416
Trade-Related Aspects of Intellectual Property Rights (TRIPS) 735
composite primary endpoints 147
compounds, synthesis of libraries 9
compression aids, for oral solid dosage forms 37
compulsory licensing conditions 735
Trade-Related Aspects of Intellectual Property Rights (TRIPS) 735
computational methods 24
advances, in drug discovery 10
computed tomography (CT), tumour status, phase II trials 280
computer systems 179
centration-effect relationship, preclinical safety testing 51
'concept papers' 362
conditional approval of medicinal products 387
conferences
ICH see International Conference on Harmonisation (ICH)
promotion of product 681
confidence intervals 197–198, 214
analysis of controlled trials 152–153, 153
calculation 197
width, determination 198
confidential information
commercial, prescription drug regulation 485
due diligence and 306
confidentiality
breach, Medicines Act 325–326
clinical trials 635–636, 759–760
anonymisation 636
Data Protection Act (1998 UK) 636
disclosure 636
Freedom of Information Act (2000 UK) 641
of information, prescription drugs, regulation of 484–485
personal data in trials 160
of submissions, TGA 563
confirmatory use, meta-analysis 215
conflicts of interest 172
conformity assessment procedure 418, 424–425, 428, 429, 430, 431
consent
'adequately informed' 292
clinical trials 351, 352, 635, 738, 753, 772, 775
Gillick competence 636
incompetent adults 351, 635, 753, 776
incompetent minors 351, 444, 635, 733, 735–736
National Health Service (NHS) 635
ethics see ethical issues/ethics
paediatric clinical trials 300
parental 289, 291, 300
presumed will 352
training on obtaining 292
voluntary, in Nuremberg Code 287, 287
see also informed consent
consumer reports 243
consumer Protection Act (1987 UK),
consumer medicine information (CMI)
consent form
constitutive properties, library design
based on 10
consumer medicine information (CMI)
contractual arrangements (in clinical
contract clinical trials, defi nition 639
contract(s)
continuous adverse reactions (type C)
contamination, historical perspectives
control groups 127, 145–147, 209–212,
in Informed Consent Form (ICF) 160
agreement 96, 171–172, 638–639
volunteers sourced by 93, 172
management of and costs 232
Lilly facility sold to Covance 526
increasing use 308
certainty of terms 638
control groups; randomised
clinical trials (RCTs)
Controlled Drugs (CDs) 465
Controlled Substances Act (1970 US) 465
supply 723
unlicensed, supply see unlicensed
medication supply, individual
patient use
Controlled Substances Act (1970 US) 465
copyright 646
Core Safety Information (CSI) 245
coronary bypass surgery, meta-analysis
216, 216
corporate social responsibility 742
corticosteroids 33
administration route 73
cosmetic sector, animal testing 633
cost(s)
animal testing 76–78, 77
cancer drug development 283
clinical trials 171
Japan 551–552
contract research organisations 232
drug discovery/development 4, 9, 219,
222, 232, 235
drug safety, increasing costs 524
in full development plan 232
US 523–524, 527
drug repurposing 22
due diligence 313
launch of drug 311
NHS see economics of health care
packaging, oral solid dosage forms 38
preclinical safety testing 76–78, 77
prescription drugs (US) 527
R&D 220, 221
see also economics of health care
cost–benefit analysis (CBA) 696
cost–consequence analysis (CCA) 695
cost-effectiveness of drugs 521
paediatric trial problems 298
cost-effectiveness analysis (CEA) 695–696
cost-effectiveness ratios 700, 700–701
cost identifi cation, economic analysis 697
cost-minimisation analysis 696
cost–utility analysis (CUA) 696–697
Council Directives see EU Directives
Council for International Organization
of Medical Science (CIOMS) 176, 238, 288
CIOMS IV 248
CIOMS V 238, 245
CIOMS VI 238, 239
CIOMS VII 238
CIOMS VIII 238, 247
CIOMS IX and X 238
CIOMS XI see,informed consent guidelines 288–289
reports 238
working groups 238
Council of Europe 361
counterfeit medicines 602–603, 606
analysis 600
anticounterfeiting strategy see
anticounterfeiting strategy
Australian regulations 571
availability 597–609
branded 598
defi nition 597–599, 605
detection 600
in developing countries, case study
602–603
EU directive 345
European Medicines Agency (EMA) 599
falsifi ed drugs differences 598
see also falsifi ed drugs
generic 598
history 599–600
identifi cation of pharmaceutical
products, EFPIA 606
illegally diverted drugs see illegally
diverted drugs
IMPACT and 599–600
defi nitions 598
incidents 2002–2010 602
international defi nitions 597–599
internet, case study 603–605
manufacturing 600–601
MEDICRIME convention 605–606
online 603–605
developmental effects (of drugs), detection, studies 58–59
devotional pharmacodynamics 298
developmental pharmacokinetics 297–298
dexlansoprazole 19
diabetes
drug discovery for 17–18
type 1 17

blood glucose as surrogate endpoint 109
diamorphine, hepatic clearance 116
diary cards 163
diet, drug interactions 124
diethylene glycol

differential timing in economic analyses

diethylene glycol

diethylstilboestrol

disease-adjusted life-years (DALYs), by disclosure of information, full, for directives, EU Directive 2001/20/EC

direct-to-consumer (DTC)
direct compression process 37–38
diphtheria–pertussis–tetanus (DPT)
dipeptidyl peptidase-4 (DPP-4) 18
digoxin

differential timing in economic analyses 699
digoxin 119
dipeptidyl peptidase-4 (DPP-4) 18
diphtheria–pertussis–tetanus (DPT) vaccine 332
direct compression process 37–38
direct-to-consumer (DTC)
medical marketing 488, 660
effectiveness 666
patients, to 665
prescription drugs 527
directives, EU see EU directives
disclosure of information, full, for investigator’s brochure (IB) 89
discharging in economic analyses 699
disease-adjusted life-years (DALYs), by WHO region 734
diseases of developing world, drug development 729, 741–742
Drugs for Neglected Diseases Initiative 742
Global Alliance for TB Drug Development (TB Alliance) 742
Global Alliance for Vaccines and Immunization 741
Group I 733, 734
Group II 733, 734, 741
Medicines for Malarial Venture 742
pediatric 437
PATH Malarial Vaccine Initiative 741
public-private partnerships (PPPs) 740, 741
social contract 742
stakeholders 742

disharmonisation 409

disintegrants, for oral solid dosage forms 37

disproportionality analysis 247
distribution and sale (of drugs), USA 475
controls (FDA) 490–491
Drug Export Amendments Act (1986 US) 466
exports 490–491
FDA Export Reform and Enhancement Act (1996 US) 467
import exceptions 490
pricing 490
unapproved new drugs 491
distribution of drugs (pharmacokinetic) 114, 114
in liver disease 125–126
paediatrics 297
distributive justice 286

divestiture, life cycle management of medicines 591
DNA
cytotoxic drugs targeting 271, 271
repair 64, 273–276, 277
unscheduled synthesis 64

DNA mutations 61
cancer pathogenesis 272
driver mutations 272

DNA vaccines 268
DNDi (Drugs for Neglected Diseases Initiative) 21
doctors
adverse drug reaction reporting by
prescription medicines promotion 683
supply of unlicensed medicines see unlicensed medicine supply, individual patient use
documentation for clinical trials 292
amendments 178, 178
archiving 181–182
ethics committee and 292
IMP see investigational medicinal product(s) (IMPs)
language and for local customs 230
preparation 157–164
alert card 163

case report forms see case report form (CRF)

informed consent form 160–161
see also informed consent investigational medicinal product dossier 162
investigator’s brochure see investigator’s brochure (IB)
master files see trial master files protocol 158–160
see also protocol of studies SOPs see standard operating procedures (SOPs)
source documents 163
subject diary cards 163
templates 158
versioning control 158
retention time 181–182
versioning control 158
donepezil 15
dosage forms
see also formulations/formulation types
dosage regimens/doses 260
children 435
drug development research 297
determination, pharmacokinetics role 119–120, 129–130
dosing frequency, controlled clinical trials 150–151
exploratory development see exploratory development (ED)

factors affecting 119, 120
first-in-human trials see first-in-human (FIH) trials
full development (FD) plan details 229
human equivalent (HED) 73, 139, 141
instructions, investigational medicinal product 165

limit dose, carcinogenicity studies 57
loading dose 119
maximum see entries beginning maximum
PK-PD analysis for 127
preclinical safety testing see preclinical safety testing
selection for controlled trials 150–151
biologics 151
starting see starting dose
trial design, pharmacokinetic data for 119–120
dose escalation design ‘3+3’ design 279
first-in-human trials 102, 103, 108
halting 107
phase I trial of cancer drugs 107
preclinical safety testing 52, 53
dose limiting toxicity (DLT), cancer drugs 279
dose-effect, preclinical safety pharmacology studies 51
dose–response
first-in-human trials 102
preclinical safety pharmacology studies 50–51
prediction in children, difficulty 298

dosing interval 119
‘dosing to toxicity’ approach 103
double-blind trials 146, 209
double-dummy technique 146, 165, 230
doxepin 23
DPT (diphtheria–pertussis–tetanus) vaccine 332
DPYD gene 277
Draize rabbit eye test 66
Draize rabbit test (skin) 65–66
dronedarone 16
drug(s) 332, 400
absorption see absorption (of drugs) active substances/similar active substances 372
ADRs see adverse drug reaction (ADR)
approvals, data on (FDA) 507
biological see biological drugs/ biologicals
branding 594, 653
categorisation 645, 720
classification changes in 474
criteria 474
CSM consultation on amendments 338
M.A and B 717–718
Medicines Commission 326–327
combinations see combination drugs compassionate use see compassionate use
complementary, Australian regulation 555, 584, 585
concentration–effect 126
factors affecting 120
contract purchase from cheap sources 717
controlled drugs see Controlled Drugs (CDs)
cost-effectiveness 521
degradation 41
design 32
development see drug development discovery see drug discovery distribution see distribution of drugs (pharmacokinetic)
elimination see elimination of drugs excetration first-in-human trials 97
see also elimination of drugs expenditure Australia 560
emerging markets 730, 732
international dimensions 343–344
Japan see Japan
Licensing Authority (LA) 326
manufacturers 324
Medical Research Council (MRC) 327
Salvarsan Committee 322
Medicines Act (1968 UK) 325–326
Medicines and Healthcare products Regulatory Agency (MHRA) 337–341
Medicines Commission 326–327
Medicines Division 336–337
monitored release 331
pharmacovigilance 344
prescription only medicines (POM) 326–327
see also prescription drugs
Safety of Drugs (CSD), Committee on 324–325
teratogenicity testing 325
thalidomide 323
UK, history see UK drug regulations
unlicensed medicines 610–631
US see Food and Drug Administration (FDA); US voluntary controls, UK (1963–1971) 323–330
see also prescription drugs; specific regulations/regulatory bodies
drug-related events, types 246
drug repurposing 5, 22–23
costs 22
number of drugs 22
for orphan diseases 21
process and reasons 22
drug safety
Australian regulations 580
authorised medicinal products 642
Food and Drug Administration (FDA) 505–506
history (UK) 321–322
increasing costs of drug development 524
media perceptions 528
public perceptions 527–529
Safety Oversight Board 506
see also safety
drug substances
requirements for administration to humans 88, 88
water interaction 36
drug targets see therapeutic targets
Drug Tariff
reference pricing and 717
unlicensed medicines 621
drug utilisation controls 531
drug withdrawal (from market) 1962–1970 (list of drugs) 330–331
1971–1982 (list of drugs) 333
arrhythmias causing 51
benoxaprofen 335, 332, 334, 334
under Committee on Safety of Drugs (CSD) 330–331
increased, by FDA 223
drug withdrawal (withdrawal syndrome) 72, 333
reactions/symptoms 72
drugability 82
Drugs for Neglected Diseases Initiative 742
dry granulation, oral solid dosage forms 38
due diligence 306–315
areas requiring 309, 309
by buyer 306, 307
checklists 309

costs 313
deal term sheet 307, 308, 313
definition 306
documents for review 309
final report 308
commercial review 311
due diligence summary 310–311
executive summary 310
format 310
pharmacoeconomic data 312
product assessment 311
product leaflet and labelling 312
product relevance to clinical setting 312
regulatory review 311
safety and risk assessment 312
writing and assembling 310–312
in life science transactions 312–313
as ongoing review process 308
patentability and patent protection 309–310
pharmaceutical physician role 306, 307, 308, 313
in private equity 312–313
project leader 307
risk–benefit 306, 310
scope 308, 309
by seller (vendor) 306, 307
team undertaking 307, 308
time-frame 307, 308
variability in 307
duplication of studies 228
duration of treatment, full development plan and 229
duty of care
breach, negligence 651
compensation liability (clinical trials) and 651
health care professional 622, 624
marketing authorisation holder 404
unlicensed medicines and 622
dynamic randomisation 207–208
E
E-1224 22
e-marketing 660, 663
medical information 664
see also marketing
Early Access to Medicines Scheme, unlicensed medicines 623–624
EC Directives see EU Directives
EC Regulations see EU Regulations
eccallantide 16
economic evaluation
in Canada 701–703
Common Drug Review (CDR) 702–703
formulary 702
compulsory 701–704
Canada 701–703
UK 703–704
cost-effectiveness ratio interpretation 700–701
incremental cost-effectiveness 700, 701
evaluating economic analyses 698–700
checklists 698, 698–700
comparators 698–699
differential timing 699
discharging 699
incremental analysis 699
placebo 698
published research 698
resource dictionaries 699
sensitivity analyses 699
validity 699–700
measuring benefits 697–698
cost identification 697
health system items 697
patient and family, costs to 697
social services items 697
societal perspective, resource items 697–698
measuring drug ‘value’ 694–701
pharmaco-economic analyses 694–695
quality-adjusted life-years (QALYs) 696–697
types of analyses 695–697
cost–benefit analysis (CBA) 696
cost–consequence analysis (CCA) 695
cost-effectiveness analysis (CEA) 695–696
cost-minimisation analysis 696
cost–utility analysis (CUA) 696–697
in UK 703–704
All Wales Medicines Strategy Group (AWMSG) 704
National Institute of Clinical Excellence (NICE) 703–704
Scottish Medicines Consortium (SMC) 704
technology appraisals 703–704
economic incentive see incentives
ecomics of health care 692–706, 702
health expenditure as % of GDP 694, 724
capita 695
NHS see National Health Service (NHS), economics
resources, identification, inclusion and exclusion 699
see also cost(s)
EDTA (ethylen diamine tetra acetic acid) 41
EEC Regulations 16
paediatric 373–374
see also EU Regulations
efalizumab 137
efficacy model, medical marketing 667–668
efficacy of drugs
Committee on Safety of Drugs requirement 324–325
likelihood, cancer drugs 280
efficacy–time profile 119
elderly 124–125
controlled trial design for 151
eligibility criteria for trials 151
exploratory development studies 108–109
drug interactions 109
in full development plan 228
mild renal impairment 151, 152
‘older’ 228
pharmacokinetics 124–125, 128
vaccine phase II studies 262
electrocardiography (ECG) 395, 464–465, 474
normal variant 91
preclinical safety pharmacology core
battery 31
electromagnetic compatibility (EMC) Directive 419, 420
electronic case report form (eCRF) 169
electronic data capture (EDC) 169, 232
electronic data communication, promotion, methods 681
exploratory development (ED) 82–112, 144
benefit: risk ratio 100
prediction 83
volunteers vs patients 92
biomarkers and surrogate endpoints in 148
critical success factor identification 83
decision milestones 84
dose range determination 83, 102–103
elderly, studies on 108–109
influencing later development study design 221
NME administration, requirements see new molecular entities (NMEs) objectives 82, 83, 8–84, 85, 111
outcomes 84, 85, 110–111
phase I and phase II studies 83
see also phase I studies; phase II studies
planning 84–86
changing after initial results 86
devising the plan 84–85, 85, 89
documentation to support 85, 85
outline 85, 85
regulatory strategy 84
preparation for first administration to humans see first-in-human trials
repeat-dosing 85, 108
pharmacokinetics 99, 108
single ascending doses 85
starting dose 90
stopping 109, 110
response 109–111
subsequent studies 108–110
drug interactions 109
in elderly 108–109
food ingestion effect 108
mass-balance studies 109
repeat doses 108
surrogate endpoints 109–110, 110
timeline 84
see also first-in-human trials; volunteer studies (healthy)
exploratory use, meta-analysis 215
export see distribution and sale (of drugs), USA
export disincentive, Pharmaceutical Price Regulation Scheme (PPRS) 712, 20
extended release formulations 33
extracorporeal membrane oxygenation (ECMO) 208
extraction ratio, of organ 116
hepatic 119
eye
irritation/sensitisation testing 66
practical safety testing 66
F
F1 hybrid mouse 56
facilities, first-in-human studies 93–94
factor Xa, inhibitor 16
failures, drug development see under drug development
false-negative errors (type II) see type II error (false-negative)
false-positive errors see type I error (false positive)
false-negative errors (type II) see type II error (false-negative)
falsified drugs 324, 345
definition 597–599
differentiation from counterfeit drugs 598
Family Health Service Authority (FHSA) 709
Family Practitioner Committees (FPCs) 709
fate of drugs 114
Fc fusion proteins 134
Fc regions 132–133
FcRn receptor binding epitope 133–134
FDA Export Reform and Enhancement Act (1996 US) 467
FDA Modernisation Act (1997) 228, 296, 301
Federal Food, Drug, and Cosmetic Act (US) 518–519
1938 464
1962, premarket review for effectiveness 502
counterfeit drugs, definition 597
Kefauver–Harris Amendments 296, 363
Federal Food and Drugs Act (1906 US) 464
Federal regulatory requirements (US) 461–462
fertility
agents affecting, reproductive toxicology studies 58
testing 58, 59
biological products 76
data interpretation in males vs females 60–61
fexinidazole 22
fibromyalgia 23
Field Safety Corrective Action 433
FIH studies see first-in-human trials
fillers, for oral solid dosage forms 37
final report 231–232
due diligence see due diligence see also clinical report (of trial results)
finances, ethical issues 291–292, 300
minor in trials 352
financial disclosure 172
fingolimod hydrochloride 14
first-in-human (FIH) trials 51, 82
administration route 97, 106
adverse reactions 95–96, 103, 106
recording, interim reviews 107
see also TGN1412 (CD28 antibody) benefit: risk ratio 100
volunteers vs patients 92
biologicals, risk factors 107, 107
recording, interim reviews 107
clinician’s qualification 93
clinician’s responsibility 87, 90, 92, 107
design 102–105
blinding 104
cohort number 103
cohort sizes 105
crossover 104, 105, 105
dose see below
parallel-study design 104, 104, 105
placebo use 104
practical aspects and conduct 106
dose/dosing
biologicals, dose selection 139–140, 140–141
biologicals, recommendation 140
increment magnitude 102
intervals between 106
number for individual subjects 103–104
range, choice 102, 102
setting for, requirements 43
single-dose see below
starting dose, choice 43, 30, 76, 90, 102, 106
to toxicity 103
dose escalation design 102, 103, 108
halting 107
dose–concentration–response relationship 96, 100, 103
dose–response 102
surrogate endpoints for 109–110
facilities and staff 93–94
healthy volunteers see volunteer(s) (healthy); volunteer studies objectives 96–102
decision on drug development 97, 99, 100
pharmacodynamics 100–102
pharmacokinetics 97–100
tolerability and safety 96–97
patients
confounding of results 92–93
healthy volunteers vs 92–93
starting doses 76
placebos 89, 104, 108
preparation 89–91
clinical trial authorisation 90–91
ethics review 90
investigator’s brochure (IB) 89–90
protocol 90
transfer from preclinical 89
protocol 90
flexibility 90, 158
IEC review 90
modifications 107
regulations, TGN1412 and 67, 140
repeat-dose 99, 108
risk minimisation 105–107, 140
high risk NMEs 107, 107
interim reviews 106, 106–107
minimal risk principle 105–106
study design and conduct 106
scaling from animal studies 73
single-dose 102, 102, 103
multiple, design 103
pharmacokinetics 99
stopping, reasons for 97
pharmacokinetics 98, 99, 99
stopping rules 90
see also exploratory development (ED); phase I studies; volunteer studies
first-pass metabolism 114, 117
fixed-dose combinations (FDC) 593
5-fluourouracil, toxicity 277
fomivirsen 20
Food, Drug, and Cosmetic Act see Federal Food, Drug, and Cosmetic Act (US)
Food and Drug Administration (FDA) 222, 461–500
21st Century Manufacturing 35
2004 regulations on foreign studies 155
2008, studies in accordance with GCP 156
accelerated approval 467–468, 472, 483, 504, 505, 530
animal drugs 474
animal testing 480
biological drugs 493–494, 502–507
biologics review 494
licence application 493–494
regulation 502–507
carcinogenicity studies 56, 57, 58
CDER see Center for Drug Evaluation and Research
Code of Federal Regulations 155, 501
Commissioner 462
counterfeit drugs, definition 597
Critical Path Initiative 530, 534
drug development, evaluation/approval
drug classifications 474–475
drug bioavailability classification 122
drug development, evaluation/approval process 501–517
abbreviated New Drug Application (ANDA) 502–503
adverse events 504
background 501–502
clinical trials 502
drug approvals, attitude evolution 503–504, 507
drug lag 503–504
drug safety 505–506
drug toxicity 505
economic incentives 531–532
effectiveness, premarket review for 502–503
ethical review and finances 291
enforcement (regulations) 494–496
drug withdrawal, increased 223
drug lag 503–504
drug toxicity 505
economic incentives 531–532
effectiveness, premarket review for 502–503
pulmonary delivery 34
rectal 35
requirements for administration to humans 88, 88–89
sterile products 34
sterile 35
two, parallel vs sequential phase III studies 229, 231
vaginal 35
fragment-based drug discovery (FBDD) 10–11, 24
advantages 11
biophysical techniques used in 11
fragments, criteria and number 10–11
library optimisation 11
success and drug number 11
France
adverse reactions in volunteer studies 225, 228
fraud 184–186
actions when suspected 185
fraud policy (US) 487–488
Freedom of Information Act (2000 UK), clinical trials 641
full development (FD) 82, 83, 144, 219–234
10-year strategic plan 224
delays, causes 230
duplication of studies 228
emerging markets and sees emerging markets
execution of plan 232–233
communication 233
contract research organisations 232
process improvement 233
quality management 233
site selection 232–233
training 233
trial prioritisation 233
minimalist programme of studies 225
as outcome of exploratory development 110–111
plan details 226–233
clinical trial supplies 229–230
coexisting medical conditions 228–229
costs 232
data management 231–232
dose form 229
dose 229
drug interactions 228–229
duration of treatment 229
human resources 231
length of programme 230–231
number of studies 227–228
for parallel vs sequential studies 229, 231
patient categories 228
patient number 226–227, 229
technology 232
timing and clinical cut-off 230
plan preparation 223–226
differentiation from competitors 225
plan structure 223–224
safety 226
sequential plan 224
strategic review of plan 224
therapeutic targets 224–226
process of taking products into 221–223
clinical perspective 221
commercial perspective 222–223
exit strategy 223
improvements 233
political influences 223
regulatory perspective 222
program number 219
senior management perspective 220–221
timing/duration 230–231, 233
see also phase II studies; phase III studies
functional observation battery 51
fundholding
General Practitioner (GP) 719
Primary Care Groups (PCGs) 720
funding
drug discovery 23, 308
FDA 463
GPs, and indicative prescribing scheme 719
Medicines Control Agency (MCA) 626
self-funding 337
fusion kinases 275
'futile cycle' 125
G
GABA receptors 298
galantamine 15
Galene 324
phase I and II studies 47
gene gun 268
generic drugs/formulations 466
bioequivalence 520
biological drugs 122, 493
competition, impact 519–521
early generic competition 533
Generic Drug Enforcement Act (1992 US) 466–467
licensing 121
pioneer drugs and 486–487, 494
registration 121
regulation 478
suitability petition 486–487
therapeutically equivalent 520
generic prescribing
NHS market 721
patents 721
generic substitution 575, 718, 744
see also biosimilars
genetic biomarkers 148
genetic disease, cancer as 272
Genentech
genetically manufactured pharmaceuticals 656
see also biological drugs/biologics
genetically modified (GM) products, Australia regulations 570
Genentech
gefitinib 275, 276, 277, 278
Gelatin capsule 33
gender
healthy volunteer studies 91–92
paediatric Regulation (EU) 435
phase I and II studies 47
gene gun 268
genetic effects 19–20
gavage, carcinogenicity studies using 57
generic drugs/formulations 466
bioequivalence 520
biological drugs 122, 493
competition, impact 519–521
early generic competition 533
Generic Drug Enforcement Act (1992 US) 466–467
licensing 121
pioneer drugs and 486–487, 494
registration 121
regulation 478
suitability petition 486–487
therapeutically equivalent 520
generic prescribing
NHS market 721
patents 721
genetic substitution 575, 718, 744
see also biosimilars
genetic biomarkers 148
genetic disease, cancer as 272
genetic manipulation, biosimilars 744
genetically manufactured pharmaceuticals 656
see also biological drugs/biologics
genetically modified (GM) products, Australia regulations 570
genomic testing
carbamazepine labelling change 523
drug effectiveness 523
warfarin dosing 522–523
see also pharmacogenetics/ pharmacogenomics
genotoxic carcinogens 42
detection 71
risk, dose and duration of exposure affecting 71–72
genotoxic impurities 71–72
lifetime intake 71
preclinical safety testing 71–72
genotoxicity 61
genotoxicity testing 61–65, 78
additional tests 62, 65
bacterial tests for gene mutation 61, 62–63
biologicals 74
chromosomal aberration assays 63
chromosome damage detection in rodents 63–64
Comet assay for DNA damage 64
false negatives/positives 65
germ cell tests 64–65
ICH guidelines 61–72
in vitro test result differences 65
mammalian cell tests for mutations 63
options and choice of assays 62
shel term, carcinogen detection 61
standard test battery 62, 65
study design 62–64
study interpretation 65
timing 61
unscheduled DNA synthesis 64
germ cell tests 64–65
German Reich Minister of the Interior 287
Germany, evaluation of medicines (1911–1963) 363
Gillick competence 635
Glutamatergic system, multiple sclerosis 13–14
GlaxoSmithKline (GSK)
Academic Discovery Performance Unit 24
franchise, medical marketing 666
Global Alliance for TB Drug Development (TB Alliance) 21, 742
Global Alliance for Vaccines and Immunization 741
global clinical trials
Good Clinical Practice (GCP) 730
patient volume by country 736
Index 807
global harmonisation, drug development 156

goingal introduction, causality of adverse events 175, 247

glomerular filtration rate (GFR) 116, 124

age-related changes, children 297–298

GLP see Good Laboratory Practice (GLP)

glucagon-like peptide 1 (GLP-1) mimic 18

glycosylation, antibodies 133

Glucuronides 125

Glucose, blood

Glucocorticosteroids, inhaled 17

Glucagon-like peptide 1 (GLP-1) mimic 18

global clinical trials 730–732

EU Clinical Trials Directive and 348, 354, 357

breaches, reporting 178–179

Australia, regulation of therapeutic goods 565

clinical trial authorisation request 90

counterfeiting, relating to 598

non-compliance 475, 498, 598, 600, 601

placebo and IMPs 230

principles and practice 335

short supply of drugs and 489–490

Good Pharmacovigilance Practice (GVP) Guidelines 242

Grahame-Smith Working Party, Yellow Card 332

grants, for drug discovery 23

Health Economics

health policy, impact on pharmaceutical market 732

Health Policy Bureau (HPB) 539

Health Technology Assessment (HTA) 556

review 2009 576–577

findings 577

healthy volunteers see volunteer(s) (healthy)

healthy volunteers, studies see volunteer studies

Heberden, William 321

Heparin, counterfeit 603

Hepaticalan extraction ratio 119

hepatic clearance of drugs 116, 125

hepatic extraction ratio 119

hepatic function 119

hepatic impairment controlled trials design 152

pharmacokinetics 125–126

hepatitis C virus (HCV) 11–12

epidemiology 11–12

genotypes/subtypes 12

hepato-renal failure, benoxaprofen 334, 335

hepatotoxicity see liver toxicity

clinical trials and 349, 353, 354, 634, 780

clinical trials and 349, 353, 354, 634, 780

compliance 88, 166

FDA and 465, 489

MHRA inspection 335, 614, 615, 622

counterfeiting, relating to 598

deviation from 489

Drug Amendments (1962 US) 465


Japan 543

pre-/post-NDA approval (FDA) 489

investigational medicinal product manufacture 164, 166, 230, 349, 353

ICH Guidelines 157, 157

in IMP dossier 90, 164

labelling of product (Annex 13) 165

legislation (EU) 366

New Drug Application (NDA) 489–490

placebo and IMPs 230

principles and practice 335

short supply of drugs and 489–490

Good Pharmacovigilance Practice (GVP) Guidelines 242

Graham-Smith Working Party, Yellow Card 332

grants, for drug discovery 23

Health Economics

health policy, impact on pharmaceutical market 732

Health Policy Bureau (HPB) 539

Health Technology Assessment (HTA) 556

review 2009 576–577

findings 577

healthy volunteers see volunteer(s) (healthy)

healthy volunteers, studies see volunteer studies

Heberden, William 321

Heparin, counterfeit 603

hepatic clearance of drugs 116, 119, 125

hepatic extraction ratio 119

hepatic impairment controlled trials design 152

pharmacokinetics 125–126

hepatitis C virus (HCV) 11–12

epidemiology 11–12

genotypes/subtypes 12

hepato-renal failure, benoxaprofen 334, 335

hepatotoxicity see liver toxicity

EU 361 before January 1995 362–364

from January 1995 to May 2004 364–366

extended harmonisation, ICH 6 454

ICH GCP see International Conference on Harmonisation (ICH)

initiatives 238

international 378

Marketing Authorisation Application (MAA) 397, 409

medical devices, standards 425

New Drug Application (NDA) 515

Office of Harmonisation 647

package leaflet and labelling 395

paediatric regulation 443

pharmacovigilance 414

post-harmonisation diversences 409

post-harmonisation referral procedures 409

pricing 416

regulatory requirements 530

technical requirements for pharmaceuticals registration 447–460

traditional herbal medicine registration 403

Voluntary Harmonised Procedure 357

see also International Conference on Harmonisation (ICH)


biosimilar drugs 494

impact 520

patent law 592

Haygarth, John 143

hazards, preclinical safety testing 43

headspace gassing 41

health, as an output of health care 693

Health and Social Care Act (2008 UK) National Health Service and 725–726

supply of unlicensed medicines for individual patient use 623

Health Canada 378, 453

health care

benefits of, measuring 697–698

communications see information economics see economics of health care

health economics see economics of health care

health policy, impact on pharmaceutical market 732

Health Policy Bureau (HPB) 539

Health Technology Assessment (HTA) 556

review 2009 576–577

findings 577

healthy volunteers see volunteer(s) (healthy)

healthy volunteers, studies see volunteer studies

Heberden, William 321

hepatic clearance of drugs 116, 119, 125

hepatic extraction ratio 119

hepatic impairment controlled trials design 152

pharmacokinetics 125–126

hepatitis C virus (HCV) 11–12

epidemiology 11–12

genotypes/subtypes 12

hepato-renal failure, benoxaprofen 334, 335

hepatotoxicity see liver toxicity

EU 361 before January 1995 362–364

from January 1995 to May 2004 364–366

extended harmonisation, ICH 6 454

ICH GCP see International Conference on Harmonisation (ICH)

initiatives 238

international 378

Marketing Authorisation Application (MAA) 397, 409

medical devices, standards 425

New Drug Application (NDA) 515

Office of Harmonisation 647

package leaflet and labelling 395

paediatric regulation 443

pharmacovigilance 414

post-harmonisation diversences 409

post-harmonisation referral procedures 409

pricing 416

regulatory requirements 530

technical requirements for pharmaceuticals registration 447–460

traditional herbal medicine registration 403

Voluntary Harmonised Procedure 357

see also International Conference on Harmonisation (ICH)


biosimilar drugs 494

impact 520

patent law 592

Haygarth, John 143

hazards, preclinical safety testing 43

headspace gassing 41

health, as an output of health care 693

Health and Social Care Act (2008 UK) National Health Service and 725–726

supply of unlicensed medicines for individual patient use 623

Health Canada 378, 453

health care

benefits of, measuring 697–698

communications see information economics see economics of health care

health economics see economics of health care

health policy, impact on pharmaceutical market 732

Health Policy Bureau (HPB) 539

Health Technology Assessment (HTA) 556

review 2009 576–577

findings 577

healthy volunteers see volunteer(s) (healthy)

healthy volunteers, studies see volunteer studies

Heberden, William 321

heparin, counterfeit 603

hepatic clearance of drugs 116, 119, 125

hepatic extraction ratio 119

hepatic impairment controlled trials design 152

pharmacokinetics 125–126

hepatitis C virus (HCV) 11–12

epidemiology 11–12

genotypes/subtypes 12

hepato-renal failure, benoxaprofen 334, 335

hepatotoxicity see liver toxicity
infl uence/relevance diagrams, benefi t–infl ammatory bowel disease 19
infl ammation, downregulation 19
information 670–691
infl uenza vaccine
infl ammatory bowel disease 19
individual autonomy 286
indirubins 15
indicative prescribing scheme 719
individual patient supply see unlicensed medicine supply, individual patient use
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised case safety reports 243
individualised treatments
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
individualised benefi t–risk assessment 249
individualised case safety reports 243
individualised treatments
immunotoxicity studies 67
investigator’s brochure (IB) 89, 161
maintenance process (M) 44
multidisciplinary 459
preclinical safety testing 44, 50, 78
quality 455–456
reproductive toxicology study design 59
safety 457
ICH 4 meeting (Brussels, 1997) 448, 449
ICH 5 meeting (San Diego, 2000) 449–451
ICH 5 meeting report 449–451
Common Technical Document (CTD) 449–450, 450
ICH 6 (Osaka, 2003) 454
assessment of innovative therapies 454
gene therapy 454
harmonisation, extended 454
medical terminology for regulatory activities (MedDRA) 454
pharmacovigilance 454
quality 454
safety and efficacy 454
ICH E2C 245
ICH E2E 251
ICH E8 221
ICH E9 201
ICH M guidelines 44
ICH M3 guidelines 49, 52, 54, 72–73
ICH M7 guidelines 72
ICH Q guidelines, impurities, testing 71
ICH R guidelines 44
ICH S guidelines 44
ICH S2R1 51
ICH S8 67
ICH Q3A(R) and Q3B(R) 71
ICH Q3D 71
key pharmacovigilance initiatives 238, 239
objective 221, 238
expert working groups 447–448
members 447
steering committee 447
organisation (2003–2007) 455
paediatric regulations 296
participants 343
person seeking consent 290
players/bodies involved 343
press releases 455–459
process 448, 448–449
harmonisation initiatives status 449
meetings and conferences 448–449
safety surveillance, contribution to 238–239
Steering Committee 343
technical requirements for drug registration 447–460
objective/purpose 447
terms of reference, revised 459
Washington, Sept 2002 453
International Federation of Pharmaceutical Manufacturers and Associations 690
International Medical Products Anti-Counterfeiting Taskforce (IMPACT) 599–600
definitions of counterfeit drugs 598
international studies 228
Internet
counterfeit drugs, case study 603–605
e-marketing 660, 663, 664
ordering products 621
pharmaceutical company websites 681
promotional methods 681
as a source of information to customer 658
interquartile range 196
intra-arterial drug administration,
preclinical safety testing 69
intramuscular drug administration,
preclinical safety testing 68, 68
intrasal administration route formulation 35
preclinical safety testing 69
intrarectal drug administration 35
preclinical safety testing 69
intratracheal drug administration, preclinical safety testing 68
invasive formulation for bioavailability determination 120, 121
see also parenteral drug administration intussusception, rotavirus vaccines and
inverted black triangle scheme 330, 332
Investigation of Medicinal Products in Geriatrics 334
investigational medicinal product(s) (IMPs) 82
bulk supplies 165
treatment 165–166
destruction 166
documentation 164–167
for master files 166
records 165–166
dosing instructions 165
emergency unblinding and 166–167
EU Clinical Trials Directive requirements 156, 164, 349, 779–780
expiry date 166
formulation changes 164
manufacture 164, 166, 230
GMP and see Good Manufacturing Practice (GMP)
manufacturers, auditing 168
order size and procedure 164
patient packs 169
presentation and packaging 165, 166
repackaging and relabelling 166
returned, management 166
safety governance at level of 239
shipping and importation 165
storage 165–166
Investigational Medicinal Product Dossier (IMPD) 90, 91, 162, 349
investigational new drug (IND) application (FDA) 162, 171, 464, 503
AIDS 481
amendments 510–511
animal testing 480
annual reports 511
benefits and risks of investigator sponsored INDS 509
‘clinical hold’ 509
case report form signing 162
treatment IND 512
treatment IND 481, 512
tracking, timing 512
unmet medical needs 511
see also Food and Drug Administration (FDA)
investigator(s)
case report form signing 162
considerations before becoming 167
fees 221
financial disclosure 172
fraudulent, motives 184
Japan, clinical trials 551
payment to 291
principal see principal investigator
reporting of serious adverse events 241
selection 167
considerations by sponsor 167
summary report on adverse events and ADRs 241
training 170, 183
trial master file see trial master files
see also clinical trial conduct
investigator meetings 170
investigator sites
approval from NHS 171
selection 232–233
investigator’s brochure (IB) 89–90, 161, 239
full disclosure required 89
updating, timing 161
investment
product-based, due diligence and 307
protection, post-authorisation 645–646
investors 306
irinotecan, toxicity 277
irritancy 65–66
irritant contact dermatitis 65–66
irritation/sensitisation testing 65–66
Irwin’s battery 31
ISO 9001 183
isotonicity, for parenterals 40

Index 811
time-frames
90-day procedure 389
120-day procedure 391
277-day procedure 384, 385
marketing authorisation holder (MAH) 237
Japan 538
legal issues 637
prosecution 236
Qualified Person for
Pharmacovigilance and 238
responsibility
PSURs 244
safety data/reports 241
mass-balance studies, exploratory
development 109
master files, of trial see trial master files
maximisation test, for allergic contact
dermatitis 66
maximum plasma concentration see Cmax
(maximum plasma concentration)
maximum rate of urea synthesis (MRUS),
ANCOVA approach 212, 212–213
maximum recommended starting dose
(MRSD) 139
biologics 140
maximum repeatable dose (MRD) 53
maximum safe starting dose,
first-in-human trials 102
maximum tolerated dose (MTD) 52, 53
cancer drugs 271, 279, 280
carcinogenicity studies 57
first-in-human trials 103
maximum well-tolerated dose (MWTD)
103, 108
MCD-386 15
me-too compounds 521, 657
mean (arithmetic) 192, 194
calculation 194
definition 194
misuse 195
population 197
mean (harmonic) 195
measles, mumps and rubella (MMR) vaccine 255, 257
measurement, scales of 191–193
MedDRA see Medical Dictionary for
Regulatory Activities (MedDRA)
media
drug promotion see promotion
drug safety perceptions 528
median 194, 195
medical advisor, medical marketing
654
‘medical affairs’ 687
Medical Defence Union (MDU),
unlicensed medicines and
628–629
medical device(s)
anticounterfeiting strategy 605
Australian regulations 555, 584–585
classification 585, 586
conformity assessment 586
exclusions 586
harmonisation 586
IVDs and biologicals 586
regulatory requirements 586
definition 421–422
EU regulations see medical device(s),
EU regulation
US regulation (FDA) 474
medical device(s), EU regulation 337,
418–434
active devices 423, 424
advanced therapy medicinal products
431–432
adverse event reporting 432
CE marking 418, 424–425, 426, 428
manufacturer declaration 426
Central Management Committee
(CMC) 421
classification of devices 423–424
Class I 423, 424
Class IIa and IIb 423, 424, 430
Class III 423, 424, 430
criteria 423
clinical investigation 429–430
criteria for investigation 429
methodology 429–430
purpose 429
competent authorities 421
conformity assessment procedures
418, 424–425, 428, 429, 430, 431
custom-made devices 425–426
definition 421–422
Directives see Medical Devices
Directives (MDDs)
drug-device borderline 422
drug–device combinations 422–423
enforcement and sanctions 433–434
essential requirements 426–427
Field Safety Corrective Action 433
General Product Safety (GPS)
Directive 432–433
obligations on distributors 433
obligations on producers 432–433
harmonised standards 425
in vitro diagnostics 430–431
common technical specifications
(CTS) 431
invasive devices 423
law on specific devices 419–420
history of 419
manufacturer
definition 427–428
information supplied by 427
outside EEA 428
manufacturer supplied information
425, 427
marketing 419
new approach’ 419, 428
Medical Device Alerts 424
Medical Device Regulations 420
national law 420
non-invasive devices 423
notified body 421, 424
packaging 427
‘placing on the market’ 428–429
‘putting into service’ 428–429
recall 430
refurbished 429
registration 425
reprocessing 426
resolution of uncertainties 420–421
safeguard clause 433
single-use medical devices 426
systems and procedure packs 426
tissue engineered products 431–432
types of safeguard clause 433–434
vigilance, adverse events reporting 432
Medical Device Alerts 434
Medical Devices Agency (UK) 337
Medical Devices Directives (MDDs) 419,
421, 426
active implantable medical devices
(AIMDs) 419
design and construction requirements
426
electromagnetic compatibility (EMC)
Directive 420
general requirements 426
in vitro diagnostics (IVDs) 419
medical devices 419
purposes 420
review of and current proposals 419
Medical Devices Regulations 420
Medical Dictionary for Regulatory
Activities (MedDRA) 180, 242,
454, 515
Standardised Queries 242
electrical equipment, medical
devices, standards 425
medical information department see
information; promotion
medical marketing see marketing
Medical Protection Society (MPS),
unlicensed medicines and
628–629
medical records
data in source documents 163
storage 163
medical research see clinical trial(s)
Medical Research Council (MRC)
first RCT 144, 206
Salvarsan Committee 322
medical statistics see statistical analysis/
statistics
Medication Guide (MedGuide) 251
medicinal product(s)
authorisation 385
see also marketing authorisation
conditional approval 387
definition 363, 367
registration, simplified 403
Medicinal Products Law of 2001,
unlicensed products, special
needs 611
Medicine Equity and Drug Safety Act
(2000 US) 469–470
medicine price index 724
medicines
herbal see herbal medicine(s)
unlicensed see unlicensed medicine
supply, individual patient use
see also drug(s)
Medicines Act (1968 UK) 325–326
administration, DHSS Medicines
Division 326
control on NHS medicines 708
information and promotion and
670–671
Licensing Authority (LA) 326
Medicines Commission 326–327
Poisons Rules 327
Provisions 326
Sections 325–326, 327
unlicensed medicines in specified
circumstances 613–614
wholesale dealer’s licences 335
Medicines and Healthcare products
Regulatory Agency (MHRA)
236–237, 337–341
advertising material
monitoring 672–673
vetting 672
advisory structure, 2005 338
complaint handling, 673
criticisms from Select Committee
338–339
facilities accreditation for first-in-
human studies 93
paediatric drug development 295–305
clinical trials 351–352, 353, 369, 438, 444–445
categories approvable 300
cost-effectiveness issues 298
difficulties 298
enrolment in multiple trials 299
ethical issues see ethical issues
ethics committees 353, 445
healthy volunteers exclusion 352
inducement 352–353
information from clinical trials 438, 445
inspections and audits 299
international trials 300
legal representation 352
need for 296–297
special populations (by age) 298, 301
studies deferred until after adult studies 302
developmental pharmacology, adults vs paediatric 297–298
pharmacodynamics 297, 298
pharmacokinetics 297–298
ethical issues see ethical issues
history and milestones 295–296
need for clinical studies in paediatrics 296–297
New Drug Application (NDA) (FDA) 487
number of medicines not studied 302
regulatory milestones 295–296
EU 296
US 295–296
regulatory requirements 301–303
EU 302
incentives 302
paediatric investigation plan see Paediatric Investigation Plan (PIP)
UK 302–303
US (mandatory requirements and reward) 301
testing of new drugs 491–492
US regulation statutes
Best Pharmaceuticals for Children Act (2002 US) 469–470
Pediatric Research Equity Act (2003 US) 470
Paediatric Investigation Plan (PIP) 301–302, 398–399, 441–442, 651
2008 marketing authorisation submission 440
aims/objectives 399, 438
application 398, 399, 401
content 439
compliance 441–442
contents 302, 399, 439
deferral of studies 302
description 301–302
legal and ethical issues 637
modifications 441
Opinion 438, 441
paediatric coordinator 441
Paediatric Use Regulation and 637
procedure 441
Request for Modification 441
rewards and incentives 442
Supplementary Protection Certificate (SPC) 442
time-frame 441
waiver 302, 398–399, 400, 438, 441
application 399–400
content 439
grounds for 440, 441
PDQC approval, role 439
paediatric population 369
parallel scientific advice from FDA and CHMP 402
physiology, special paediatric 436, 436–437
see also adolescents; children; neonates
paediatric Regulation (EU) 289, 296, 302, 435–445
administration of medicines 436
adverse drug reactions (ADRs) 365, 437
adverse events 437
aims/objectives 438–439
case study 435
changes applying to industry 439–440
clinical trials see paediatric drug development, clinical trials
deferrals 440
dosages 435
EU Database on Clinical Trials (EudraCT) 443
EU regulations 289, 296, 388
European Medicines Agency (EMA) role 442–444
Expert Advisory Committee (PDQC) 439
see also Paediatric Committee (PDQC)
gender differences 435
harmonisation 442
history 437
information on paediatric drugs 438
legal and ethical issues 637
long-term effects of medicines 437
methodology 437
marketing authorisation 440
medicines legislation 368–369
networks 443–444
expert 444
paediatric 444
paediatric research 444
new paediatric medicines regulation 438
off-label use 443
off-patent medicines 443
orphan diseases 437
paediatric drug research 438
paediatric provision 369, 400
Paediatric Use Marketing Authorisation (PUMA) 438, 442
paediatric waiver see under Paediatric Investigation Plan (PIP)
physiology, special paediatric 436, 436–437
PIPs see Paediatric Investigation Plan (PIP)
preterm and term infants 435, 437
stakeholders 443
sunset clause 388
suspected unexpected adverse reactions 365
urgent safety restrictions 414–415
Variations, post-approval, to marketing authorisations 404, 409
Paediatric Use Marketing Authorisation (PUMA) 302, 438, 442, 637, 651
application rate 442
legal and ethical issues relating to medicinal products 637
off-patent medicines 442, 443
Paediatric Use Regulation 1901/2006 637, 651
paediatric waiver see Paediatric Investigation Plan (PIP)
palliative therapy 270, 271
Pandemic and All-Hazards Preparedness Act (2006 US) 470
pandemic vaccines availability 407, 533
Pandemic and All-Hazards Preparedness Act (2006 US) 470‘panel screening’ 161
parallel trial design 149–150
advantages/disadvantages 149, 149
first-in-human trials 104, 104, 105
phase III trials 149, 150
randomisation after enrolment 150
parental consent 289, 291, 300
parenteral drug administration 34, 35
carcinogenicity studies 57
preclinical safety testing 68
parenteral formulations
advantages 34
depot-based 33
disadvantages/adverse effects 34
parenterals (injectables) 38
filtration 40
free from particulate matter 39
free from pyrogens 39
isotonicity 40
pH management 40–41
stabilisation 41
stability 41
vehicles for 40
see also sterile products
PARP 275
actions/functions 277
inhibition 277
particle size 33
oral solid dosage forms 37
particular patient see unlicensed medicine supply, individual patient use
particulates, in injectables 39
partnering solutions 308
partnerships 220
partition, postnatal effects of drugs 61
patent(s) 645, 646–647
application for 646–647
Australia, regulations 584–585
context of 520
counterfeiting 598
exclusions 646
expiry 466, 518, 732
extension, Australia 585
generic drugs 466
generic prescribing 721
Hatch–Waxman Act (1984 US) 466, 592
legal issues 592, 645, 646–647
life 504, 532, 666
litiigation 647
paediatric use 439, 442
pipeline patents 735
preparation 310
protection 309–310
Supplementary Protection Certificate (SPC) 438, 650
UK 646
US regulations 504
usage patent (indications) 368
patent attorneys 310
‘patent busting’ strategy, vardenafil 4
discovery 4
patentability, due diligence and 309–310
PATH Malaria Vaccine Initiative 741
general considerations 50
in vitro vs in vivo studies 50
influencing later development study design 221
for new chemical entity 86, 86
regulatory guidelines 50
secondary pharmacodynamic activity 87
supplementary studies 52
preclinical safety testing 36, 42–81, 87–88
administration routes see administration routes
animal numbers 76–78, 77
animal species used 43, 49, 52
animal testing see animal testing
for biologicals see in vitro
secondary pharmacodynamic activity
regulatory guidelines 50
animal testing
animal species used 43, 49, 52
animal numbers 76–78, 77
for biologicals
duration
dose escalation studies 52, 53
dose
damage/toxicity types 42
carcinogenicity studies see carcinogenicity studies
dose toxicity types 42
dose increase, low frequency adverse events 43
maximum repeatable (MRD) 53
maximum tolerated (MTD) 52, 53
range-finding (DRF) 53
single ascending (SAD) 53
see also repeat-dose studies (below)
dose
for 36
duration
administration routes and 68, 68
low frequency adverse events 43
maximum 53
non-rode studies 53
repeat-dose studies 49, 52, 53
effects of animal testing 44, 76–78, 77, 632–633
excipients 69
extrapolation to humans 43, 73
biologicals 74
difficulties/problems 67, 87–88
metabolites and 70
failure to predict human risk 43, 75
fixed-dose study 53
generic toxicity package generated 48, 48–49
genotoxicity see genotoxicity testing
ICH guidelines see International Conference on Harmonisation (ICH)
immunotoxicology see immunotoxicology
in vitro assays, as animal studies 66, 78
irritation/sensitisation testing 65–67
see also immunotoxicology
metabolites 69–70
national/international regulations 42–43
necrosis for? 78, 87
objectives 42, 87
‘omic’ technologies 43, 44–46
predictivity for human toxicity 43, 75
enhancing 46
rationalisation 78
recovery period 54, 55
regulatory control 44
repeat-dose studies 52–55
biologicals 74
control animals 54–55
daily dose (low/high dosage) 54
definitive toxicity studies 53–54, 52
for 53
duration 49, 52, 52
genotoxicity testing 62
maximum repeatable dose 53
minimum number of animals for 52
study interpretation 54–55
reproductive toxicology see reproductive toxicology
risk–benefit 47–49
scaling from animals to humans 43, 73
preparation 89
single-dose studies 50, 51, 52, 53
genotoxicity testing and 62
specialty areas 69–73
challenge stimuli, safety 88, 89
dependence potential 72–73
excipients 69
impurities and genotoxic impurities 71–72
liver toxicity 70–71
metabolites 69–70
see also animal testing
preclinical scientists 89
preclinical testing stage see preclinical testing safety
PREDICT – 1 Study 249
Predictive Safety Testing Consortium (PTSC) 46
preformation stage 36
pregnancy, thalidomide disaster see thalidomide disaster
pregnancy reports, pharmacovigilance 243
premarket approval, Biological Products Act (1902 US) 464
premarketing phase, adverse events and ADRs 241
premature trial termination, contractual arrangements 171–172
premium free medicine, Pharmaceutical Beneﬁts Scheme (PBS) 574
prescribing
generic, NHS market 721
GP fundholding 719
indicative prescribing scheme 719
off-label see off-label prescribing;
unlicensed medicine supply
physician 491–492, 708
UK 708
prescription charges, NHS 709–711
from April 2012 710–711
exemptions 710
Scotland, and Wales 710
Prescription Drug Marketing Act (1987 US) 466
anticounterfeiting strategy 607
Prescription Drug User Fee Act (PDUFA, 2002) 467, 471, 483, 486
prescription drugs 395, 474, 594–595
advertising 643, 670, 681
application data for use without prescription 396
Australia 555
categorisation 477, 643
change in classiﬁcation see under EU Procedures
costs 527
criteria 396
drugs no longer available in UK 708
Durham–Humphrey Amendment (1951 US) 464
expenditures 521
Australia 560
NHS 658, 658, 659, 709
see also drug(s), expenditure
GP prescribing 708
internet advertising 681
investigative new drug (IND) 480–482
legal status 397
medical marketing 663
NDA 478, 480, 482–484
NHS see National Health Service (NHS)
no NDA 479–480
Prescription Drug Marketing Act (1987 US) 466
Prescription Drug User Fee Act (1992 US) 467
promotion see promotion
registration with TGA, Australia 565
registration in Australia 556–561
registration in Japan see Japan
registration in UK see UK drug regulations
registration in US 477–493
see also drug regulations; Food and Drug Administration (FDA)
switch to OTC drug class 594–595, 720
US (FDA) 474–475
UK, dispensing 708
see also prescription only medicines (POM) class
prescription event monitoring 330
prescription only medicines (POM) class 326–327, 720
see also prescription drugs
‘presumed will’ 352
see also consent
preterm infants 436, 436, 437
price premium, National Health Insurance (NHI) 546
pricing (of drugs)
Australian regulations 574, 575
see also under Australia, regulation of therapeutic products
biosimilars 749
EU wholesale 416–417
France 227–228
harmonisation 416
imports and 490
Japan, NHI 546
Memorandum of Understanding 2010 576
Pharmaceutical Beneﬁts Pricing Authority (PBPA) 559, 560
phase III trials of cancer drugs 281
PPRS see Pharmaceutical Price Regulation Scheme (PPRS)
public concerns 526–527
reference, Drug Tariff and 717
special patient contribution arrangements 575
therapeutic group premiums 575–576
in US 465, 490, 520
value-based (VBP) scheme 716–717, 725
‘pricing study’ 228
Primary Care Groups (PCGs) development 719–720
fundholding 720
unified budget 720
Primary Care Trusts replacement with clinical commissioning groups (CCGs) 726
unlicensed medicines 627
see also NHS Trusts
primary endpoints 147, 192, 202, 204, 221
co-primary 147
composite 147
quality assurance (QA) 183, 184
audits 182, 184
functions 184
staff 184
in trials 184
Quality Assurance (QA) auditors, organisation pre-trial 168
Quality by Design (QbD) 32, 35–36
concept 35
implementation 35–36
regulatory dossier for products 36
‘quality by testing’ approach 35
quality control (QC) 183–184
definition 183
history, in UK 319–320
testing 35
quality management 183–186
in full development 233
manufacturing 242
quality management systems, medical devices 425
quality of life (QoL), prospective, phase III trials of cancer drugs 281
quantification, in medicine 191
quantitative data 191
discrete vs continuous 191

R
rabbits, preclinical safety testing in 43, 59
radiation, absorbed doses 126
radiolabelled drugs
doses, and studies using 126
elimination of drugs 126
radiolabelled materials, mass-balance studies 109
Raf kinase inhibitors 11
Raf kinase inhibition 10
randomisation 130, 150, 206–208
allocation of number 169
bias in 208
bias reduction 143–144, 206, 207
blocked (advantages/disadvantages) 206
crossover trial design 150
definition 206
dynamic allocation (minimisation) 207–208
ethical issues 208
multicentre studies 206–207
parallel trial design 150
play-the-winner (RPW) design 208
reasons for 206
stratified (advantages/disadvantages) 206–207
unrestricted 206
randomised clinical trials (RCTs) 519
cancer drugs 280
history 143–144
see also clinical trials(s); controlled clinical trials
randomised discontinuation design 281, 282
randomised-play-the-winner (RPW) design 208
RANK–RANKL binding 19
Rapid Alert 415
rapporteur, Marketing Authorisation Application (MAA) 382
rare diseases see orphan diseases; orphan drug(s)
ras H2 model 56
rating scales 191, 193
ordinal 191, 193
multiple 193
rats
spermatozoa, fertility testing 60
see also rodents, preclinical safety testing
R&D see research and development (R&D)
R&D companies 220
reactive chemicals, genotoxicity testing 62
reactive intermediates, hepatotoxicity 70
reasonable causal relationship, definition 241
recalls, Australia, regulations 570–571
receptor activator of nuclear factor-kB ligand (RANKL) 19
receptor occupancy 100
receptor tyrosine kinase (RTK) 273, 275
activation in cancer 272–273, 273
EGFR 272, 274
rechallenge, risk after adverse events 175
recombinant DNA technology 132, 134
biosimilars 744
recommended phase II dose (RP2D) 280
recruitment (for trials) 172
after ethics committee approval 171
cancer drugs phase III studies 281
competition for patients 221, 231
difficulties, for radiolabelled drug studies 126
improved by payments 291–292
monitoring visits and 173
time required for 230
vaccine phase III studies 262
volunteers 94, 94–95, 172
see also volunteer(s) (healthy)
rectal formulation 35
‘red cell ghosts’ 40
reducing agents 41
Reference Member States (RMS) 368
reference pricing, Drug Tariff and 717
reference ranges 177
referrals to CHMP see Committee for Medicinal Products for Human Use (CHMP)
‘reflection papers’ 362
reformulation of products 592–593
registration
accelerated approval
cancer drugs 282–283, 505
FDA 467–468, 472, 504, 505, 530
generic drugs/formulations 121
harmonisation, technical requirements 447–460
herbal medicines 403
medical devices, EU regulation 425
new drugs 4
see also new drug(s); New Drug Application (NDA)
Prescription drugs, with TGA (Australia) 565
of trade marks 647
regression-to-the-mean 210
regulations
adverse drug reactions see Yellow Card scheme
Australia see Australia, regulation of therapeutic products
enforcement 494–496
EU see EU Regulations
increased, cost increase 222
Japan see Japan
medical devices see medical device(s)
UK, history see UK drug regulations
US see Food and Drug Administration (FDA); US
see also drug regulations; specific regulations
regulatory approval for trial 171
requirements, IMP dossier 162
regulatory authorities 222
approval needed, protocol preparation 158
benefit-risk evaluation 248
pharmacovigilance 236–237, 237, 240
reporting requirements during trials 178–179
safety governance 240
UK 336
regulatory control
concerns over surrogate endpoints 149
preclinical safety testing 44
role in pharmaceutical development 32
regulatory dossier for products, Quality by Design (QbD) 36
regulatory inspections 182
triggered 182
see also inspections
regulatory procedures 235
regulatory requirements, paediatric studies see paediatric drug development
regulatory review, due diligence report 311
regulatory strategy, in exploratory development planning 84
regulatory submissions, clinical pharmacokinetics 113, 129
relative risk (RR) 204–205
relative risk–benefit, prescriber’s decision 225
‘release for use process’ 39
remote data entry 169
renal clearance 116, 125
first-in-human trials 97
neonates 298
in renal impairment 151–152
see also clearance of drugs
renal impairment
controlled trials 151–152
mild, in healthy elderly 151–152
pharmacokinetics 125
renin, suppression 16
repeat-dose studies see under preclinical safety testing
reporting
ADRs see adverse drug reaction (ADR)
adverse events see adverse events
case report form (CRF) errors 173
during trials, requirements 178–179
final, at end of trial 231–232
see also clinical report (of trial results)
Good Clinical Practice (GCP) breaches
178–179
misuse/overdose 242
off-label drug use 242
periodic see periodic reporting
reproductive toxicology studies 58–61
aims 58–59
animal species 60
antifertility effects
females 60–61
males 60
biologicals 75–76
data evaluation/interpretation 60–61
developmental effects 58–59, 88
general reproductive effects
healthy volunteer studies in men 91–92
ICH study design (‘preferred option’) 59
juvenile toxicity studies 60
number of animals used 76–78, 77
segments (1–3) 59
study types 59
timing of studies 59–60
research company-sponsored clinical trials 634–635
see also NHS Trusts
designs 768
paediatric 438
networks 444
Pediatric Research Equity Act (2003) US 470
research and development (R&D) Australia 560
companies involved 220
costs 220, 221
decreasing productivity, in USA 522
due diligence process 306, 309
emerging markets 728–729
government cost sharing 532
high industry profits and 527
models 742
number of drugs 220
Pharmaceutical Price Regulation Scheme (PPRS) 712–713
process 47
resources 729
research ethics committees see ethics committees (ECs)
research nurses 93
resource dictionaries 699
respiratory syncytial virus (RSV) vaccine 265
respiratory system, preclinical safety pharmacology core battery 52
responder(s) 192
responder rates 191–192
determination 192
response evaluation criteria in solid tumours (RECIST) 280, 281
response rate (RR), phase II cancer drug trial endpoint 280
restricted access (to drugs), risk minimisation 251
retroviral therapy 13
returning reflex, preclinical safety pharmacology studies 52
rilpivirine 13
risk 105
absolute 153, 153
categories/examples, paediatric clinical trials 299
definition 235, 367
evaluation 251–252
factors contributing 107
minimal see 'minimal risk'
mitigation strategies 251–252
relative 153, 153
risk assessment in due diligence report 312
ethical issues 292
risk–benefit 192, 235
Advisory Committee opinions 235
balance, drugs 367
in clinical trial phases 47–48, 48
decreasing risk with programme progression 48
due diligence 306, 310
ethical issues 292
in preclinical safety testing 47–49
problems in assessing 193
vaccines see vaccine(s)
see also benefit: risk ratio
risk–benefit analysis, vaccines 255
risk–benefit assessment/evaluation 248–249
context 248
hierarchy of evidence 248
methodologies 248–249
paediatric clinical trials 298–299, 299
personalised medicines 249
Risk Evaluation and Mitigation Strategy (REMS) 251, 505, 528, 529
modifications 251
New Drug Application (NDA) 512
risk management 528
Australia 555
New Drug Application (NDA) 483–484, 512
planning 250–252
European 251
minimisation of risk 250–251
New Drug Application (NDA) 512
proactive management 250
systems 414
Therapeutic Goods Administration (TGA), Australia 554
risk management plan (RMP) 251, 414
aims 251–252
Risk Minimisation Action Plans (RiskMAPs) 251
Ritchie Index 201
rituximab 275
rivaroxaban 16
rivastigmine 15
rodents, preclinical safety pharmacology 43, 47
safe handling precautions 65
safety
authorised medicinal products 642
drugs see drug safety
in due diligence report 312
first-in-human trials 96–97
general safety measures 335–336
monitoring in paediatric clinical trials 301
pharmaceutical physician role 172–173
phase II trials see phase II studies
preclinical testing see preclinical safety pharmacology
risk management plan (RMP) 251
safety governance 239–240
Safety Governance Boards 239
Safety Matrix Teams (SMT) 239, 247
Safety of Drugs (CSD), Committee on 324–325
Safety Oversight Board 506
safety-related suspension, revocation or variation 415
Salmonella typhimurium, reverse mutation assay 62–63
sample size 213–214
confidence interval and 198
determination 213–214
in full development plan 227
primary endpoint determining 147
randomised trials 150
responder rate determination 192
samples, drug (promotional) see drug(s)
samples 699
sarcoma 55
saturation transfer difference, fragment-based drug discovery 11
scaling factor 73
scarification 267
Schenen Agreement 361
scientific advice assistance and, EU Procedure see EU Procedures from CHMP 400–402
final advice letter 401
HTA Bodies and Payers, joint scientific advice 402
parallel scientific advice from FDA and CHMP 402
procedure 401
report 401
team 401
written procedure 401
Scientific Advice Working Party (SAWP) 376, 400
expertise, structure and roles 376
fees 400
pre-submission meeting 400
time-frame 400
Scientific Advisory Groups (SAGs) CHMP 376–377
answers and comments 377
members 377
European Medicines Agency (EMA) 374
scientific misconduct 184–186
scientific necessity, ethical principle 299
Scotland, prescription charges 710
Scottish Medicines Consortium (SMC), economic evaluation 704
screening high-throughput (HTS) 3, 9, 46–47
low-throughput in vivo 9
Scripps Research Institute 23
scurry, remedies, early trial 143
SCYX-7158 22
second generation products 592–593
secondary endpoints 147
adding, preventing 147
Secret Remedies 322
sedative actions of drugs, preclinical safety pharmacology studies 52
SELEX (Systematic Evolution of Ligands by EXponential enrichment) 20
sensitisation, testing eye 66
immunotoxicology 66–67
skin 65–66
sensitivity analyses 699
Sentinel System 512, 528
Food and Drug Administration (FDA) 506
serine/threonine kinase, GSK-3 as 15
serine NS3/4A protease inhibitors 12
serious adverse events (SAEs) 511
criteria determining 240–241, 241
protocol instructions 158
SUSAR see suspected unexpected serious adverse reactions
(SUSARs)
see also adverse drug reaction (ADR), serious
serious adverse reactions see adverse drug reaction (ADR)
serotonin-norepinephrine reuptake inhibitor (SNRI), drugs
serotonin system, children/infants
serious adverse reactions
sildenafil (Viagra)
signal detection 246–248
serotonin-norepinephrine reuptake inhibitor (SNRI), drugs
serotonin-norepinephrine reuptake inhibitor (SNRI), drugs
signal detection 246–248
sarcopenia 246
signal transduction 151
single-dose studies 47
single use medical devices 426
similar biologics see biosimilars
similar medicinal product 372
definition 366
single-dose studies 47
single-blind trials 146, 209
single cell gel electrophoresis (SCGE) assay 64
single-dose studies 47
drug interaction studies 123
first-in-human trials see first-in-human (FIH) trials
genotoxicity testing and 62
pharmacokinetics in renal impairment 125
phase I studies 47
preclinical safety testing 50, 51, 52, 53, 62
single-use medical devices 426
siRNA (small interfering RNA) 20
silotriglipin 18
site management organisations (SMOs) 168
Sjögren’s syndrome 15
skin, irritancy of drugs/agents 65–66
sleeping sickness, drug development 22
small and medium-sized enterprises (SMEs) 368
incentives 370
small interfering RNA (siRNA) 20
small molecular weight chemical new chemical entities (SMW NCEs) 134
monoclonal antibody differences 134, 135
smallpox eradication 254–255
smallpox vaccine 254, 267, 463
social media
due diligence and 307
subjects influenced by information on 307
socioeconomic factors, risk–benefits of vaccines affected by 255–256, 257
software developers 179
solid oral dosage forms see oral solid dosage forms
solid-phase chemistry 9
solid-support, compounds binding 9
solid tumours, status, phase II trials of cancer drugs 280
solubility of amorphous materials 33
solubility of drugs 36
standard deviation 192, 196, 197, 214
standard deviation of the mean 197
Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) 582
standard operational procedures (SOPs) 163–164
full development plan 233
preparation 163–164
trial-specific and general guidance 164
volunteer studies (healthy) 93, 95
Standardised Medical Dictionary for Regulatory Activities (MedDRA)Queries 242
Staphylococcus aureus, methicillin-resistant (MRSA), drug treatment 22
starting dose
biologicals, in first-in-human trials 139–140, 140, 141
recommendation 140
choice in first-in-human trials 43, 50, 90, 102, 106
patients 76
exploratory development (ED) 90
maximum safe, FDA 73
volunteer studies (healthy) 50, 73, 90
statins 110
counterfeit 603
statistical analysis/statistics 181, 189–218
ANOVA type approach 212, 212–213, 213
basic principles 193–200
calculations
arithmetic mean 194
confidence intervals 197
power 213–214
sample size 213–214
choice of 212–213
factors affecting 212
definitions
mean, median and mode 194
meta-analyses 214
number needed to treat (NNT) 205
randomisation 206
descriptive 193, 194–197
inter-quartile range 196
mean, median and mode 194–195
measures of location/central tendency 194–195
measures of variability 195–197
range between values 195–196
design issues and 200–214
bias prevention see bias
blinding see blinding
control groups see control groups
endpoint choice 204–205
exploratory/pragmatic trials 202–204
stability of drugs
excipients, role 69
parenterals 41
pH profile 33
stability testing 37
staff
animal testing 632
first-in-human studies 93–94
numbers, full development plan 231
quality assurance (QA) 184
training 170, 183
volunteer studies (healthy) 93–94
Stallinon 363
standard deviation 192, 196, 197, 214
population 197
standard error of the mean 197
Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) 582
standard operational procedures (SOPs) 163–164
full development plan 233
preparation 163–164
trial-specific and general guidance 164
volunteer studies (healthy) 93, 95
Standardised Medical Dictionary for Regulatory Activities (MedDRA) Queries 242
Staphylococcus aureus, methicillin-resistant (MRSA), drug treatment 22
starting dose
biologicals, in first-in-human trials 139–140, 140, 141
recommendation 140
choice in first-in-human trials 43, 50, 90, 102, 106
patients 76
exploratory development (ED) 90
maximum safe, FDA 73
volunteer studies (healthy) 50, 73, 90
statins 110
counterfeit 603
statistical analysis/statistics 181, 189–218
ANOVA type approach 212, 212–213, 213
basic principles 193–200
calculations
arithmetic mean 194
confidence intervals 197
power 213–214
sample size 213–214
choice of 212–213
factors affecting 212
definitions
mean, median and mode 194
meta-analyses 214
number needed to treat (NNT) 205
randomisation 206
descriptive 193, 194–197
inter-quartile range 196
mean, median and mode 194–195
measures of location/central tendency 194–195
measures of variability 195–197
range between values 195–196
design issues and 200–214
bias prevention see bias
blinding see blinding
control groups see control groups
endpoint choice 204–205
exploratory/pragmatic trials 202–204
stability of drugs
excipients, role 69
parenterals 41
pH profile 33
stability testing 37
staff
animal testing 632
first-in-human studies 93–94
numbers, full development plan 231
quality assurance (QA) 184
training 170, 183
volunteer studies (healthy) 93–94
Stallinon 363
standard deviation 192, 196, 197, 214
population 197
standard error of the mean 197
Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) 582
standard operational procedures (SOPs) 163–164
full development plan 233
preparation 163–164
trial-specific and general guidance 164
volunteer studies (healthy) 93, 95
Standardised Medical Dictionary for Regulatory Activities (MedDRA) Queries 242
Staphylococcus aureus, methicillin-resistant (MRSA), drug treatment 22
starting dose
biologicals, in first-in-human trials 139–140, 140, 141
recommendation 140
choice in first-in-human trials 43, 50, 90, 102, 106
patients 76
exploratory development (ED) 90
maximum safe, FDA 73
volunteer studies (healthy) 50, 73, 90
statins 110
counterfeit 603
statistical analysis/statistics 181, 189–218
ANOVA type approach 212, 212–213, 213
basic principles 193–200
calculations
arithmetic mean 194
confidence intervals 197
power 213–214
sample size 213–214
choice of 212–213
factors affecting 212
definitions
mean, median and mode 194
meta-analyses 214
number needed to treat (NNT) 205
randomisation 206
descriptive 193, 194–197
inter-quartile range 196
mean, median and mode 194–195
measures of location/central tendency 194–195
measures of variability 195–197
range between values 195–196
design issues and 200–214
bias prevention see bias
blinding see blinding
control groups see control groups
endpoint choice 204–205
exploratory/pragmatic trials 202–204
Therapeutic Goods Act (1989 Australia) 554, 557, 558
Therapeutic Goods Administration (TGA) 554, 561
activities/roles 554–555
adoption of EU guidelines 562
adverse drug reaction (ADR) 569, 570
adverse event reporting 570
Advisory Committee on Prescription Medicines (ACPM) 566–567
applications for registration 561–562
categories 562
assessment and monitoring 554
Australian Public Assessment Report (AusPAR) 567–568
clinical evaluation 566
confidentiality of submissions 563
consumer medicine information (CMI) 569
counterfeit good and tampering 571
data exclusivity 564
data protection 563–564
amendments 564
evaluation process 565–566
time-frames 556, 562–563
fee penalties 563
gene technology, products 570
Good Manufacturing Practice (GMP) inspections 565
harmonisation 569
human embryos/human embryonic stem cells (HESC) 570
marketing application decisions, appeals against 568
milestones 563
Office of Medicines Authorisation (OMA), review 567
Orphan Drug Program 564
paediatric indications 569
incentives 569
pharmacovigilance, post-marketing 569–570
post-ACPM and delegate’s decision 567
pre-submission planning phase 566
prescription medicines, registration 565
priority evaluations 564–565
product information (PI) 568–569
non-safety-related changes 568
safety-related changes 568
submission data 568–569
recalls 570–571
reform 584
registration 561–571
administrative requirements 562
applications 561–562
e-CTD 562
regulation 554
risk management 554
submission data, products 568
submission of new data 566
additional data 566
supplementary data 566
transparency 563, 570
therapeutic index 123
in exploratory development 83, 103
high, dose level 103
low, trials in renal impairment 152
therapeutic orphans 295
therapeutic protein see protein therapeutic agent
Therapeutic Substances Act (1925) 322
Therapeutic Substances Act (1937) 556
therapeutic targets 223
development plan preparation 224–226
monoclonal antibodies advantages 213
neglected tropical diseases 21
new molecular entities (NMEs) profile 83
off-target binding 9
selection/identification 3, 9
validation 3
therapeutically equivalent generic drugs 520
Therapeutics for Neglected and Rare Diseases (TRND) programme 21
theriac 319, 320
Threshold of Toxicological Concern (TTC) 71
'tagged' (generic) 71–72, 72
thrombopoietin receptor agonist 21
thymidine kinase (TK) 63
ticagrelor 16
time, drug discovery/development 4
time-dependent kinetics 108
time to maximum plasma concentration (t_max) 115, 121
tissue cross-reactive study 74
tissue engineered products 431–432
tissue microarrays (TMA)s 45
fraction (time to maximum plasma concentration) 115, 121
TMC207 21
tolerability 96
first-in-human trials 96–97
safety vs 97
tolerance
CNS drugs 108
definition 97
toll-like receptors (TLRs) 267
topical drug administration 57
carcinogenicity studies 57
preclinical safety testing 69
topical drugs, cutaneous toxicity 65
topical formulation 35
TOPS database 95
torsade de pointes (TdP) arrhythmia 51
tumour suppressor genes 272, 277
TRND programme 21
tubular reabsorption 116
Tufts Institute 227
tumorgenesis 272
tumour(s) 55
benign vs malignant 55
formation 272
preclinical safety testing 42
on-treatment biopsy 279
see also cancer
tumour necrosis factor (TNF), osteoclast formation 19

tumour necrosis factor (TNFα), monoclonals binding to 19

tumour suppressor genes 272, 277
degradation, therapeutic target 275–276
Tuskegee syphilis study 289
Twee 80
type I error (false positive) 200, 201
elevation using interim analysis 201
multiple subgroup testing impact 201
probability calculation 201
sample size effect 213, 214
type II error (false-negative) 148, 213–214
sample size effect 213
tyrosine kinase inhibitors (TKIs) 275, 276
resistance to 278
Index 833

repeat-dose study 53
safety consideration 92
standard operating procedures (SOPs) 93, 95
starting dose 50, 90
FDA guideline 73
tolerability information 96
see also exploratory development (ED); first-in-human (FIH) trials; phase I studies
vulnerable subjects 351
clinical trials 351
exclusion from trials to protection, shift 351
mental incapability 161, 290, 291
minors 352
protection 351–352, 752
see also children; minors

W
waiver
class 400, 441
clinical trial agreement 762
drug see drug(s), waiver
paediatric see Paediatric Investigation Plan (PIP)
on periodic report (PSUR format) (FDA) 245
product-specific waiver 400
Wales, prescription charges 710

warfarin
-genomic diagnostic testing 522–523

single-dose study, for drug interactions 123
‘wash-out’ period 161
water
bacteriostatic, for injection 40
drug substance interactions 36
sterile, for injection 40
water for injection (WFI) 40
WaterLOGSY, fragment-based drug discovery 11
wet granulation
advantages/disadvantages 38
oral solid dosage forms 38
whistle-blower 184
WHO-ART 242
wholesale dealers, UK licences 335
wholesale distribution, pricing and reimbursement
Australia 574–575
EU procedures 416–417
withdrawal of drugs see drug withdrawal
women of child-bearing potential (WOCBP), in clinical trials 59–60
World Health Organization (WHO) 238
ADR Monitoring Centre 334
Adverse Reaction Terminology (WHO-ART) 242
counterfeit medicines 599
epidemiology and disease burden 733
GCP guidelines see Good Clinical Practice (GCP)
pharmacovigilance 239, 239

World Medical Association (WMA) 155, 751
Declaration of Helsinki review 156
see also Declaration of Helsinki

X
X-Omics technologies 43, 44–46
X-ray crystallography, fragment-based drug discovery 11

xanomeline 15
XPA mice 56

Y
Yellow Card scheme 330–335, 333, 721, 767
doctor reports 331, 332
efficiency review, Working Party 332
extension, report submission 333
failure of, example 331
information currently required 333
number of reports 333, 334
pilot scheme 330
rates of reporting 330
report number 330
successes 334
see also adverse drug reaction (ADR)
‘Yellow Perils’ 330

Z
Zaprinast 3
zidovudine (AZT) 223